GlassScriptPhysician profile
Shiv K Desai
NPI 1285920751
$10,741.45
in general payments reported to CMS, 2019-2025
42 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $374 · 2021: $1,379 · 2022: $2,563 · 2023: $1,852 · 2024: $1,912 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,952 · Education: $13.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,951.95 |
| Education | $13.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,642.61 | 2020-2025 | Mavyret, Rinvoq, Skyrizi |
| Medtronic, INC. | $1,016.00 | 2021-2025 | Barrx, Interstim, Nexpowder |
| Boston Scientific Corporation | $968.20 | 2019-2025 | Exalt Model D, General - Metal Stents - G.I. |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $909.47 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $665.28 | 2021-2024 | Zeposia |
| Pfizer INC. | $651.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $616.82 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $346.96 | 2023-2025 | |
| Cook Medical LLC | $321.18 | 2019-2024 | Fusion, Saeed |
| Janssen Biotech, INC. | $310.25 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Olympus America INC. | $270.68 | 2022-2023 | High Definition Lcd Monitor |
| Conmed Corporation | $255.00 | 2020-2025 | Conmed Hemostasis, Conmed Biliary |
| Janssen Scientific Affairs, LLC | $135.04 | 2022-2025 | Tremfya |
| Apollo Endosurgery US INC | $134.57 | 2022 | |
| Daiichi Sankyo INC. | $123.87 | 2021-2023 | Injectafer |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $121.83 | 2023-2025 | Vegzelma, Yuflyma |
| Ambu INC. | $97.55 | 2022 | |
| Redhill Biopharma INC. | $94.81 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $89.78 | 2021-2025 | |
| Romark Laboratories, Lc | $87.20 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $83.01 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $78.53 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $72.83 | 2021-2023 | |
| Ardelyx, INC. | $68.29 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $62.46 | 2024-2025 | Voquezna |
| Vivus LLC | $62.12 | 2022-2025 | Pancreaze |
| Madrigal Pharmaceuticals | $58.96 | 2024-2025 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $57.03 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $46.21 | 2023 | Linzess |
| Braintree Laboratories, INC. | $45.02 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $43.08 | 2021 | |
| Ucb, INC. | $36.04 | 2021 | |
| Qol Medical, LLC | $30.23 | 2022-2023 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $24.64 | 2022 | |
| Fresenius Kabi USA, LLC | $23.22 | 2023 | Idacio |
| Mauna Kea Technologies, INC. | $21.98 | 2025 | |
| Blueprint Medicines Corporation | $16.80 | 2023 | |
| Lilly USA, LLC | $14.81 | 2025 | Omvoh |
| Novo Nordisk INC | $14.68 | 2025 | Wegovy |
| Sandoz INC. | $14.23 | 2023 | Hyrimoz |
| Organon LLC | $8.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiv Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.